Ardsley Advisory Partners LP Aldeyra Therapeutics, Inc. Transaction History
Ardsley Advisory Partners LP
- $610 Million
- Q2 2025
A detailed history of Ardsley Advisory Partners LP transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Ardsley Advisory Partners LP holds 2,050,000 shares of ALDX stock, worth $11.4 Million. This represents 1.29% of its overall portfolio holdings.
Number of Shares
2,050,000
Previous 400,000
412.5%
Holding current value
$11.4 Million
Previous $2.3 Million
241.35%
% of portfolio
1.29%
Previous 0.52%
Shares
13 transactions
Others Institutions Holding ALDX
# of Institutions
134Shares Held
34.9MCall Options Held
244KPut Options Held
51.6K-
Knoll Capital Management, LLC Miami, FL5.48MShares$30.3 Million14.27% of portfolio
-
Perceptive Advisors LLC New York, NY4.05MShares$22.4 Million0.68% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$20.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.5MShares$19.4 Million0.0% of portfolio
-
Aqr Capital Management LLC Greenwich, CT1.47MShares$8.16 Million0.0% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $323M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...